{"id":5666,"date":"2023-09-04T03:16:27","date_gmt":"2023-09-04T03:16:27","guid":{"rendered":"https:\/\/cm.vastapps.dev\/tcia-collection\/qin-prostate-repeatability\/"},"modified":"2023-09-13T12:02:13","modified_gmt":"2023-09-13T12:02:13","slug":"qin-prostate-repeatability","status":"publish","type":"tcia_collection","link":"https:\/\/cm.vastapps.dev\/tcia-collection\/qin-prostate-repeatability\/","title":{"rendered":"QIN-PROSTATE-REPEATABILITY"},"featured_media":0,"template":"","citation-tax":[],"cancer_types":["Prostate Cancer"],"citations":[4598,4599,4600,2925,4601],"collection_doi":"10.7937\/K9\/TCIA.2018.MR1CKGND","collection_download_info":"Click the Versions tab for more info about data releases.","collection_downloads":[5211],"full_export":"
\n
\n
\n
\n

Summary<\/h2>

This is a dataset with multiparametric prostate MRI applied in a test-retest setting, allowing to evaluate repeatability of the MRI-based measurements in the prostate. There is very limited data about the repeatability in mpMRI of the prostate, while such information is critical for establishing technical characteristics of mpMRI as imaging biomarker of prostate cancer. <\/span><\/p>

Data was provided by the Brigham and Women's Hospital team. Data collection was supported by U01 CA151261 (PI Fiona Fennessy)<\/strong>. Preparation of data for public sharing was supported by U24 CA180918 (<\/strong><\/span>http:\/\/qiicr.org<\/span><\/a><\/strong>) (MPI Andrey Fedorov and Ron Kikinis)<\/strong>.<\/span><\/p><\/p>

Type of cancer: Confirmed or suspected prostate cancer<\/span><\/p>

Acquisition Protocol: Standard prostate mpMRI protocol implemented at Brigham and Women's Hospital was used in this study. For a given patient, we aimed to maintain similar protocol settings, and used the same scanner hardware and software configurations for both the baseline and repeat examinations, which were acquired within 2 weeks of time. All of the imaging studies were acquired at 3 Tesla magnet strength.\u00a0 Due to the scanner hardware upgrade in the middle of the study, 6 of the patients had baseline and repeat study performed on a GE Signa HDxt platform, software release 15.0_M4A_097.a, while the remaining 7 patients were scanned on a GE Discovery MR750w, software release DV24.0_R01_1344 (General Electric Healthcare, Milwaukee, WI). Transrectal coil within an air-filled balloon (Medrad Inc., Warrendale, PA) was used in all imaging studies. mpMRI protocol included T2-weighted, Diffusion Weighted (DW) (b-values of 0 and 1400 mm\/s2) and Dynamic Contrast Enhanced (DCE) sequences. Detailed acquisition parameters are listed in Table 1 of [1]. DWI Apparent Diffusion Coefficient (ADC) and DCE subtract maps (further referred to as SUB; computed as the difference between the phase corresponding to the contrast bolus arrival and the baseline phase) were generated using the scanner software. <\/span><\/p>

The imaging data is accompanied by the following types of derived data:<\/span><\/p>